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Background: We evaluated candidate circulating serum cytokines, chemokines and growth factors in patients
with locally/regionally advanced melanoma receiving neoadjuvant ipilimumab with toxicity and clinical outcome.
Methods: Patients were treated with ipilimumab (10 mg/kg IV every 3 weeks, 2 doses) before and after surgery.
xMAP multiplex serum testing for 36 functionally selected cytokines and chemokines was performed at baseline
and at six weeks (following ipilimumab). Based on our prior data, the association of IL-17 and immune related
colitis was tested. Serum cytokines were divided into functional groups (Th1, Th2, Regulatory, Proinflammatory)
and were assessed at baseline and week 6 using sparse-group Lasso modeling to assess the association of various
cytokine groups with progression free survival (PFS). The linear combination of the cytokines/chemokines in this
model was then used as a risk score and a Kaplan-Meier curve was generated to examine the association of the
dichotomized score and PFS.
Results: Thirty-five patients were enrolled whose staging was: IIIB (3; N2b), IIIC (30; N2c, N3), IV (2). Median follow-up was
18 months. Among 33 evaluable patients, median PFS was 11 months (95 % CI = 6.2–19.2). IL-17 was found to correlate
significantly with the incidence of grade 3 diarrhea/colitis when measured at baseline (p = 0.02) with a trend towards
significance at 6 weeks (p = 0.06). In the modeling analysis, at baseline, the linear combination of 2 regulatory cytokines
[TGF- β1 (ρ = 0.19) and IL-10 (ρ= -0.34)] was significantly associated with PFS (HR 2.66; p = 0.035). No significant
correlations with clinical outcomes were found in examining the week 6 cytokines.
Conclusions: Baseline IL-17 level was significantly associated with the later development of severe diarrhea/colitis while
the combination of baseline TGF- β1 and IL-10 levels were associated with therapeutic clinical outcome after neoadjuvant
ipilimumab. These findings warrant further investigation and validation.
Trial registration: ClinicalTrials.gov Identifier NCT00972933.
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Patients with clinically detectable lymphatic metastasis
(American Joint Committee on Cancer stage IIIB-C)
carry a poor prognosis with a risk of relapse and death
that approaches 70 % at 5 years [1–3]. Complete surgical
excision and regional lymph node dissection followed by
adjuvant therapy with high dose interferon alfa-2b (HDI)
has been the standard of care for this group of patients
[1]. The host immune response is known to be relevant* Correspondence: tarhiniaa@upmc.edu
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article, unless otherwise stated.to disease outcome in melanoma and host cytokine
and cellular immune responses may potentially be used
to predict prognosis and response to therapy [4–6]. A
better understanding of the regulation of the host
effector and suppressor cellular and cytokine elements
in response to melanoma may provide valuable mechan-
istic clues that may be exploited to predict therapeutic
response to immunotherapy, including treatment with
ipilimumab.
Ipilimumab is a human immunoglobulin-G (Ig G1k)
anti- cytotoxic T-lymphocyte-associated protein (CTLA)-
4 antibody which has been approved by the United Statesle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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advanced inoperable melanoma based on phase III trial
results [7]. However, treatment is associated with signifi-
cant immune related adverse events and durable thera-
peutic benefits appear to be confined to a subgroup of
patients. Therefore, it is of critical importance to define
biomarkers that may predict clinical response and the risk
of toxicity in patients treated with ipilimumab [8]. Assess-
ment of these biomarkers in peripheral blood is particu-
larly desirable given the facile accessibility, and ability to
perform highly standardized repetitive assessments of
blood biomarkers.
We conducted a neoadjuvant evaluation of ipilimumab
administered at 10 mg/kg for patients with locally/region-
ally advanced melanoma, where we have previously re-
ported significant clinical activity and immunomodulatory
changes in the circulation and the tumor microenviron-
ment with ipilimumab [9]. In this report, we evaluated a
group of functionally selected cytokines and chemokines
divided into 6 subgroups, and their association with clin-
ical outcome. IL-17 is one of the central inflammatory cy-
tokines upregulated in inflammatory bowel disease [10].
Therefore, we tested the association of IL-17 with the risk
of immune mediated colitis after neoadjuvant ipilimumab.
Patients, materials and methods
Patients
All eligible patients were 18 years or older with clinic-
ally detectable local and/or regional melanoma (of cuta-
neous, mucosal or unknown primary site of origin).
The Institutional Review Board of the University of
Pittsburgh approved the study and the written informed
consent that was obtained from all patients participat-
ing in the study.
Study design and treatment
Patients were required to receive two doses of ipilimu-
mab at 10 mg/kg intravenously given 3 weeks apart
(induction). Surgery was planned 6–8 weeks after the
initiation of ipilimumab,neoadjuvant therapy. After re-
covery from surgery, 2 additional doses of ipilimumab
3 weeks apart were planned (maintenance). Blood speci-
mens for correlative studies were planned at baseline
and 6 weeks (before surgery)—and then at 3, 6, 9 and
12 months or at progression.
Toxicity and response assessments
For Adverse Event (AE) reporting, the description and
grading scales of NCI Common Terminology Criteria for
Adverse Events version 3.0 were used. Imaging studies were
carried out at baseline, after 6–8 weeks of therapy (before
surgery) and then at 3 months intervals for response assess-
ment. Responses were not confirmed due to performance
of definitive surgery to render the patient free of disease.Statistical methods
The original study design and statistical plan have previ-
ously been published [9]. This report compares the correla-
tive cytokine and chemokine blood levels studied among
patients who experienced diarrhea/colitis and those who
did not, using the Wilcoxon sum rank test. Given the ex-
ploratory nature of this study, no adjustment for multiple
testing was done—and the nominal p-values are reported.
Sparse group Lasso (SGL) modeling analysis was used to
evaluate the association of different subgroups of the 36
functionally selected cytokines (assessed at baseline and at
week 6) with progression free survival (PFS). Cytokine
levels were scaled so that all cytokines have the same scale.
This method allowed us to simultaneously fit the model
and select the markers and group(s) associated with benefit
as defined by PFS. More importantly, it allows the incorpor-
ation of prior functional group information into the model-
ing. The functional group information was defined by the
biological function as shown below. A regular Cox propor-
tional hazard (CoxPH) model was fitted to the markers se-
lected by SGL. The linear combination of the cytokines
(i.e. the product of the cytokine level and the CoxPH model
coefficients) was then used as the risk score. We dichoto-
mized the risk score at the median and generated Kaplan-
Meier (KM) survival curves to examine the association of
the risk score and PFS.
Baseline descriptive statistics were performed on all
evaluable patients for demographic variables, laboratory
parameters, toxicity and therapeutic efficacy in relation
to disease PFS. PFS were estimated by the Kaplan-Meier
method.
Laboratory methods and corresponding statistical
analyses
Blood processing
Red top vacutainer tubes (no anticoagulant) were used
for serum collection and all samples were processed
within 24 h of collection (samples received before 5 pm
were processed upon receipt, those arriving after 5 pm
were processed the following morning). Serum samples
were centrifuged at 2500 rpm for 10 min at 4 °C accord-
ing to laboratory standard operating procedures (SOPs)
and single use aliquots of each patient’s sera were then
stored at -80 °C. The laboratory freezers were monitored
continuously for any temperature fluctuations, and
maintained the samples at -80C.
Multiplex serum cytokine analysis
Functionally selected 36 serum cytokines were tested.
These included Th1 type cytokines (IFN-γ, IL-12 (p40/p70),
IL-15, IL-17, IL-2, IL-7, IP-10), Th2 (IL-13, IL-5, IL-4), pro-
inflammatory (IL-1α, IL-1β, IL-6, TNF-α, IL-1RA, IL-2R,
IL-8, CRP, IL-17, IFN-α), immunoregulatory (TGF-β1, IL-
10, PGE2), growth factor (VEGF, G-CSF, EGF, HGF, FGF-
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CCL3/MIP-1α, CCL4/MIP-1β, CCL2/MCP-1, CXCL9/MI
G, CCL11/Eotaxin). The xMAP serum assay for these cyto-
kines was performed according to the manufacturer’s
protocol (BioSource International (Camarillo, CA)) as pre-
viously described [11] and laboratory SOPs, and analyzed
on the Bio-Plex suspension array system (Bio-Rad Labora-
tories, Hercules, CA). Experimental data was analyzed
using five-parametric curve fitting and assay controls in-
cluded kit standards and multiplex QC controls (R & D
Systems). Inter assay variabilities for individual cytokines
were 1.0 to 9.8 % and intra-assay variabilities were 3.6 to
12.6 % (information provided by Biosource International
and validation performed in our laboratory).
Results
Patient characteristics, treatment details, efficacy and
safety
Thirty five patients were enrolled between 2/2010 and
10/2012. Eight patients had newly diagnosed melan-
oma whereas 27 patients had recurrent disease after
treatment that included surgery. Twenty nine patients
had cutaneous primary tumors, five mucosal and one
with unknown primary melanoma. Eighteen patients
had in-transit metastatic melanoma. On retrospective
review, two patients demonstrated stage IV disease at
baseline determined through the progression of previ-
ously questionable/undetected findings [9]. By stage,
patients were classified as IIIB (3; N2b), IIIC (30; N2c,
N3) and IV (2). Patient demographics and baseline
disease characteristics were previously published [9].
A median of 4 cycles of ipilimumab per patient were
administered with a total of 106 cycles [9]. Efficacy
data has been previously reported [9]. Briefly, the me-
dian follow-up for patients at risk of progression was
17.6 months and for patients who were still alive was
16.1 months. The median PFS was 10.8 months, 95 %-
CI (6.2, 19.2). The probability of PFS at 6 andFig. 1 Serum levels of interleukin-17 (IL-17) in patients treated with neoadj
(p = 0.02) and at week 6 (p = 0.06)12 months was 0.72, 95%CI (0.53, 0.84) and 0.47,
95%CI (0.29, 0.63). The probability of survival at both
6 and 12 months was 0.97, 95%CI (0.78, 0.99). AEs re-
lated to ipilimumab have been reported previously [9].
These include the immune related AEs that were con-
sidered related to ipilimumab. Twenty patients (57 %)
experienced diarrhea/colitis, including 9 (26 %) grade
1, 6 (17 %) grade 2 and 5 (14 %) grade 3. There were
no grade 4 or higher events [9].
Association of IL-17 level and diarrhea/colitis
To identify potential circulating biomarkers of efficacy and/
or toxicity, serum samples were tested for levels of a broad
array of analytes. Blood IL-17 levels at baseline were found
to correlate significantly with the incidence of grade 3 diar-
rhea/colitis (p = 0.02), while this association remained with
a trend towards significance at 6 weeks (p = 0.06). Figure 1
IL-17 was not significantly associated with all grades of
colitis. We found an association between baseline IL-17
and any grade 3 irAE (similar to colitis, which was not sur-
prising given that over 50 % of patients with irAE events
had colitis), but the association was slightly less significant
(P = 0.03). When we examined all grade irAE (including
colitis, rash, hepatitis, endocrinopathies, pancreatitis), there
was no significant association.
Association of cytokines at baseline with PFS
The examination of individual cytokines with clinical
outcome did not reveal any significant associations with
disease outcome. Previous studies have identified groups
of analytes as signatures of clinical outcome measures
[12–16]. Therefore, we grouped our data into general
functional groups based on their characterized roles in
immune modulation as listed in Materials and Methods.
In modelling analysis only one group of cytokines
(the regulatory group) was selected by SGL as signifi-
cantly associated with PFS. With further examination of
these data grouped functionally, we identified a modeluvant ipilimumab correlate Gr3 diarrhea/colitis when tested at baseline
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appeared to be a risk marker for progression, while un-
expectedly, TGF-β1 appeared to be a marker of non-
progression. The coefficients for the association of these
two markers with PFS were 0.18 and -0.32 respectively.
The dichotomized risk score based on these 2 markers was
significantly associated with PFS (p = 0.036, HR = 2.66) as
shown in Fig. 2. None of the type I cytokines tested corre-
lated with clinical outcome.
Association of cytokines with PFS at 6 weeks
The examination of the correlation of blood levels of
individual cytokines with clinical outcome did not reveal
significant associations. Similarly, the sparsed group
lasso analysis results did not reveal any combination of
markers that significantly correlate with PFS.
Discussion
Ipilimumab has been shown to improve the survival of
patients with advanced melanoma, but benefits only a
subset of patients. Predicting the likelihood of clinical
benefit from ipilimumab or the risk of developing tox-
icity remains an elusive goal. There is a critical need to
define a biomarker or a set of biomarkers that can
predict clinical response and the risk of toxicity in pa-
tients receiving ipillimumab. Major efforts in biomarker
studies are ongoing and preliminary data are very en-
couraging, including gene expression signatures [9, 17],
exome sequencing studies [18], and CD8 expression
within the tumor microenvironment [19]. In this study,
we evaluated the baseline and on-treatment serum levels
of cytokines that have been functionally selected. The as-
sociation of these blood cytokines with toxicity and clinical
benefit after ipilimumab is novel and of potential clinicalFig. 2 Baseline serum levels of TGF-β1 and IL-10 correlate with
progression free survival (PFS)importance for this first systemic therapy to be approved in
metastatic melanoma on the basis of survival benefits. Such
an analysis is an important component of evaluating the
host immune response to melanoma and may provide
valuable mechanistic data, as well as allowing the improved
prediction of benefit for patients who are considered for
treatment with ipilimumab.
IL-17 is one of the central inflammatory cytokines and
has been shown to be upregulated in the blood of pa-
tients with inflammatory bowel disease [10]. Therefore,
the evaluation of IL-17 in patients with ipilimumab-
associated inflammatory colitis is well justified. Pairwise
comparisons of serum IL-17 levels in patients with col-
itis (n = 13) compared to those without immune related
AEs (irAEs) (n = 16) demonstrated significantly higher
serum IL-17 levels in patients with colitis at week 7
(p = 0.007) and week 12 (p = 0.02) [20]. In the present
study, we observed a significant correlation between the
risk of subsequent development of grade 3 immune-
mediated diarrhea, for the first time with circulating
blood IL-17 assessed at baseline, among patients enter-
ing neoadjuvant therapy for regionally advanced melan-
oma. We also confirmed the prior reported association
of elevated levels of IL-17 on treatment at week 6, with
the development of grade 3 immune-mediated diarrhea
(grade 3 was the worst grade obesreved in our study).
The occurrence of irAEs has been reported to be associ-
ated with the overall clinical benefit in patients receiving
ipilimumab [21–26]. This supports the notion that these
AEs are related to the mechanism of action of ipilimu-
mab, and its reversal of immune tolerance. The ability to
predict a patient’s risk for developing irAEs such as
autoimmune colitis may significantly impact clinical
care. These data support further evaluation of the blood
levels of this cytokine as a predictor of risk for this AE.
Such predictive testing for inflammatory colitis may be
most productive in combination with other serologic
and genetic markers of inflammation known to be asso-
ciated with inflammatory bowel disease in the popula-
tion. To our knowledge, no associations between other
cytokines and toxicity have been reported in the past.
Melanoma patients have been shown to have a different
pattern of serum cytokines when compared to healthy con-
trols [12, 27]. Yurkovetsky et al, reported a higher level of
IL-1α, IL-1β, IL-6, IL-8, IL-12p40,IL-13, GM-CSF, MCP-1,
MIP-1α, MIP-1β, IFN-α, TNF-α, EGF, VEGF, and TNF-RII
in the plasma of melanoma patients compared with healthy
controls [12]. High serum levels of IL-1β, IL-1α, IL-6,
TNF-α, and chemokines MIP-1α and MIP-1β measured
before treatment (HDI) were positively associated with RFS
[12]. High levels of VEGF and fibronectin have been associ-
ated with lack of clinical response to high dose IL-2 therapy
and worse overall prognosis in metastatic melanoma and
renal cell carcinoma patients [28].
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suppression [29] Blockade of TGFβ has shown therapeutic
potential in preclinical tumor models and in clinical trials
[29]. Our observation that higher serum TGFβ is associated
with lack of tumor progression is quite unexpected. In
contrast, we find that high baseline IL-10 levels to be corre-
lated with tumor relapse. While TGFβ can have immune
suppressive effects in vitro and in certain model systems
in vivo [29], this observation may represent the presence of
an ongoing protective immune response which is being
endogenously counter-regulated in a TGFβ dependent fash-
ion. This may be similar to our observations that increased
Treg in the circulation is a positive prognostic marker
(while Treg in tumors is a negative prognostic biomarker)
[9]. However, our observation is not unique. A recent study
reported that chemotherapy-responsive metastatic melan-
oma patients had higher serum TGFβ1 levels compared
with chemotherapy-unresponsive patients (p = 0.05) [30]. In
addition, patients with elevated serum TGF-β1 concentra-
tions had a trend towards a favorable overall survival out-
come compared to those with lower levels (median 30.1 vs.
20.9 months, respectively) in that study [30]. Similarly, high
serum TGF-β1 level was found to be associated with
improved survival in patients with breast cancer [31].
Therefore, this finding warrants further investigation.
We grouped serum cytokines functionally and con-
ducted a modeling analysis in order to evaluate the lin-
ear combination of combinations of multiple cytokines
belonging into four different functional groups, and to
evaluate the impact of ipilimumab more rationally. The
findings of our study should be taken as hypothesis-
generating since further studies are needed to validate
our findings and to refine our understanding of the
role that readily assessed circulating peripheral blood
cytokines may play in predicting the clinical impact of
immunotherapy in patients with melanoma, both toxic
and therapeutic. As with any assessment of serum or
plasma-based biomarkers, pre-analytic variables of time
between blood draw and processing, tube type, as well
as storage conditions and freeze/thaw cycles can impact
results. Our single institution study utilized a CAP/
CLIA central laboratory which participates in external
proficiency testing and which has substantial expertise
in this area to reduce as many variables as possible.
The ongoing intergroup phase III trial E1609 led by
ECOG-ACRIN in which ipilimumab is being evaluated
as postoperative adjuvant therapy for melanoma at
3 mg/kg and 10 mg/kg in comparison to high dose
interferon-α provides an opportunity to further investi-
gate and validate these results.
Conclusions
In patients with regionally advanced melanoma who en-
rolled in a trial of neoadjuvant therapy with ipilimumab at10 mg/kg, baseline pretreatment IL-17 is here for the first
time shown to be significantly associated with the risk of
subsequent development of severe immune-mediated diar-
rhea. The baseline levels of TGFβ1 and IL-10, as a dichoto-
mized risk score based on these 2 markers, are significantly
associated with PFS. The observed prognostic role of high
TGFβ1 levels (unlike those of IL10) is supported by other
reports in the literature. These findings warrant further
investigation and confirmation in larger trials.
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